当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.

Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.

Abstract：

:In this case-control study, interview data on smoking habits were available for 179 de novo cases (116 with cytogenetic data) of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Smoking habits were compared with a pooled set of population controls and hospital controls (diagnosed with malignant melanoma). Each pack-year of smoking increased the risk of MDS with 1.3% (95% CI 0.1-2.6%), corresponding to an estimated excess risk of 71% (95% CI 3-180%) for 40 pack-years. Associations between smoking and the specific aberrations -5/5q-, -7/7q-, and +8 in AML and MDS were indicated but the estimates were imprecise.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Björk J,Johansson B,Broberg K,Albin M

doi

10.1016/j.leukres.2008.10.009

subject

Has Abstract

pub_date

2009-06-01 00:00:00

pages

788-91

issue

6

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(08)00468-2

journal_volume

33

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: effect of vascular endothelial growth factor on development of the microenvironment.

    abstract：:To elucidate the biological characteristics of chronic myelogenous leukemia (CML) cells, we observed morphological and functional changes of CML cells during primary long-term culture, in which their morphology changed to that of myofibroblasts with similar molecular characteristics to the parental CML cells including...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.09.019

    authors： Shirasaki R,Tashiro H,Mizutani-Noguchi M,Kawasugi K,Shirafuji N

    更新日期：2011-05-01 00:00:00

  • Response to intermediate and standard doses of IFN-beta in hairy-cell leukaemia.

    abstract：:Thirteen hairy-cell leukaemia patients were treated with IFN-beta (6 X 10(6) IU/m2) for 7 days, alternate weeks, for three cycles. IFN-beta was then continued at the same dose twice a week for 24 weeks. Treatment was discontinued in 2 non-responders and 2 partial responders (1 haem PR, 1 path PR) because of complicati...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90071-g

    authors： Liberati AM,Fizzotti M,Di Clemente F,Senatore M,Berruto P,Falini B,Martelli MF,Grignani F

    更新日期：1990-01-01 00:00:00

  • Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

    abstract：:Mutation of the tumor suppressor PTEN results in loss of its PI3-kinase counteracting function. PI3-kinase stimulates tumor formation by PKB/Akt-mediated cell proliferation and prevention of apoptosis. PI3-kinase may also activate Rho-GTPases and their regulatory GEFs to promote invasion. Here we have analyzed the fun...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.034

    authors： Strumane K,Song JY,Baas I,Collard JG

    更新日期：2008-01-01 00:00:00

  • The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.

    abstract：BACKGROUND:Chronic Myeloid Leukemia (CML) is characterized by the overproduction of BCR-ABL, a tyrosine kinase with constitutive activity, in which the majority of CML patients have e13a2 or e14a2 transcripts. Reckoned the possible associations between the hematologic and molecular features of the disease, a profound u...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2021.106512

    authors： Ghalesardi OK,Khosravi A,Azizi E,Ahmadi SE,Hajifathali A,Bonakchi H,Shahidi M

    更新日期：2021-01-19 00:00:00

  • Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.

    abstract：:We investigated the therapeutic activity of recombinant erythropoietin (r-EPO) in association with thalidomide in 30 patients with myelodysplastic syndromes (MDS), previously treated with r-EPO (n.15, group A) or thalidomide (n.15, group B) as single agents, respectively, without any significant benefit on their anemi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.08.020

    authors： Musto P,Falcone A,Sanpaolo G,Bodenizza C

    更新日期：2006-04-01 00:00:00

  • c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.

    abstract：:c-Myc has been implicated in a variety of hematologic malignancies including Burkitt's lymphoma. Targeting c-Myc driven growth pathways could be therapeutically useful but might require the identification of critical downstream proteins. Here we show that the serine-threonine kinase PBK/TOPK is frequently overexpresse...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.11.010

    authors： Hu F,Gartenhaus RB,Zhao XF,Fang HB,Minkove S,Poss DE,Rapoport AP

    更新日期：2013-04-01 00:00:00

  • Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.

    abstract：:The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or acute leukaemias is rare. Inherited chromosomal abnormalities are also rare events in the general population. In chronic myeloid leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described as...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.06.003

    authors： Silva PM,Lourenço GJ,Bognone RA,Delamain MT,Pinto-Junior W,Lima CS

    更新日期：2006-01-01 00:00:00

  • Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression.

    abstract：:Deregulated myc, bcl-2 and/or TP53 gene expression is associated with non-Hodgkin's B cell lymphomas (B-NHLs). Emu-N-myc transgenic mice that misexpress N-myc protein and carry a non-disrupted bcl-2 gene develop indolent B cell lymphomas reminiscent of the B-NHL, follicular lymphoma. Tumors from mice with end-stage di...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00103-4

    authors： Samant SA,Sheppard RD

    更新日期：1999-10-01 00:00:00

  • Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia.

    abstract：:Bone marrow cells from 109 patients (median age 60) with newly diagnosed acute myeloid leukaemia (AML) were prospectively immunophenotyped (IP) and the prognostic value of monoclonal antibody (MAB) reactivities was analysed to detect differences in complete remission rates and survival, not only between groups of MAB ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90071-z

    authors： Kristensen JS,Hokland P

    更新日期：1991-01-01 00:00:00

  • Physical and functional interactions between hematopoietic cell-specific ETS transcription factors and homeodomain proteins.

    abstract：:To examine the possibility that ETS family transcription factors, PU.1, SPI-B, ELF-1, ERG-3, ETS-1 and TEL, and homeodomain proteins, HOXA10, HOXC13, MEIS1 and PBX1B, function cooperatively, we investigated their interactions. In luciferase assays, HOXA10 and HOXC13 augmented the activity of PU.1 and SPI-B while dimin...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.07.002

    authors： Yamada T,Shimizu T,Sakurai T,Nanashima N,Kihara-Negishi F,Suzuki M,Fan Y,Akita M,Oikawa T,Tsuchida S

    更新日期：2009-03-01 00:00:00

  • An autologous tumor vaccine for CLL.

    abstract：:Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.03.002

    authors： Zhu F,Khatri I,Spaner D,Gorczynski RM

    更新日期：2018-05-01 00:00:00

  • Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

    abstract：:DNA aneuploidy has been used as a genetic marker of malignancy in multiple myeloma (MM). CD38 and CD138 expression and absence of CD22 and CD19 may define plasmacells (PC). Several authors support evidences of circulating plasmacells, and their role in relapse after autologous stem cell transplantation has been hypoth...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.09.015

    authors： Santonocito AM,Consoli U,Bagnato S,Milone G,Palumbo GA,Di Raimondo F,Stagno F,Guglielmo P,Giustolisi R

    更新日期：2004-05-01 00:00:00

  • Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia.

    abstract：:Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the ex...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.10.034

    authors： Sato N,Kishi K,Toba K,Watanabe K,Itoh H,Narita M,Takahashi M,Aizawa Y

    更新日期：2004-07-01 00:00:00

  • Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

    abstract：:The prognostic effect of hypogammaglobulinemia (HGG), clinical and biologic characteristics on the infection risk and outcome has been retrospectively analyzed in 899 patients with stage A chronic lymphocytic leukemia (CLL). Low levels of IgG were recorded in 19.9% of patients at presentation, low levels of IgM and/or...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.02.011

    authors： Mauro FR,Morabito F,Vincelli ID,Petrucci L,Campanelli M,Salaroli A,Uccello G,Petrungaro A,Ronco F,Raponi S,Nanni M,Neri A,Ferrarini M,Guarini AR,Foà R,Gentile M

    更新日期：2017-06-01 00:00:00

  • Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.

    abstract：:This study was aimed to illustrate the significance of minimal residual disease (MRD) assessment on day 22 in childhood acute lymphoblastic leukemia. MRD were measured on day 22, day 36, week 12, month 6 and month 12 by four-color flow cytometry. The 5-year cumulative incidence of relapse was significantly different f...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2012.03.014

    authors： Xu XJ,Tang YM,Shen HQ,Song H,Yang SL,Shi SW,Xu WQ

    更新日期：2012-08-01 00:00:00

  • Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma.

    abstract：:Mantle cell lymphoma (MCL) is an aggressive malignancy and new treatment modalities must be established to increase patient survival time. In the search for new therapeutic targets, reliable and well-characterised in vitro models are essential. In this study, we have characterised three MCL cell lines (SP53, Granta 51...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.06.009

    authors： Ek S,Ortega E,Borrebaeck CA

    更新日期：2005-02-01 00:00:00

  • Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

    abstract：:Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/U...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.leukres.2018.08.022

    authors： Miyazaki Y,Tuechler H,Sanz G,Schanz J,Garcia-Manero G,Solé F,Bennett JM,Bowen D,Fenaux P,Dreyfus F,Kantarjian H,Kuendgen A,Malcovati L,Cazzola M,Cermak J,Fonatsch C,Le Beau MM,Slovak ML,Santini V,Lübbert M,Macieje

    更新日期：2018-10-01 00:00:00

  • An in vitro study of blast cell metabolism in acute myeloid leukaemia using the MTT assay.

    abstract：:We have utilized the MTT assay to measure the metabolic activity of cells from the bone marrow of 55 patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and non-clonal disease. Doubling dilutions of cells were exposed to MTT for 3-4 h. The mean optical density of the formazan produced by each c...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00163-8

    authors： Elgie AW,Sargent JM,Taylor CG,Williamson C

    更新日期：1996-05-01 00:00:00

  • Insertion (10;11)(p11;q23q24) in two cases of acute monocytic leukemia.

    abstract：:An insertion (10;11)(p11;q23q24) was found in bone marrow metaphase cells from two children with acute monocytic leukemia (AMoL-M5b). This rearrangement involves a small chromosomal segment of 11q and may be misinterpreted as a deletion of 11q. Insertion (10;11) may represent a new recurring abnormality involving 11q ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90140-7

    authors： Le Beau MM,Bitter MA,Kaneko Y,Ueshima Y,Rowley JD

    更新日期：1985-01-01 00:00:00

  • Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.

    abstract：:Compound 48 (C48) is a novel dual ligand for peroxisome proliferator-activated receptor alpha and gamma (PPAR alpha/gamma). Culture of imatinib-sensitive and -resistant CML cell lines with C48 resulted in a strong growth inhibition which associated with G0/G1 cell cycle arrest. However, it showed no obvious toxicity t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.11.023

    authors： Bertz J,Zang C,Liu H,Wächter M,Possinger K,Koeffler HP,Elstner E

    更新日期：2009-05-01 00:00:00

  • Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.

    abstract：:Aberrant promoter methylation may contribute to the hematopoietic disturbances in myelodysplastic syndromes (MDS). To explore a possible mechanism, we therefore analyzed expression of DNA methyltransferase (DNMT) subtypes kinetics and aberrant promoter methylation of key regulatory genes during MDS hematopoiesis. An i...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.08.014

    authors： Hopfer O,Komor M,Koehler IS,Freitag C,Schulze M,Hoelzer D,Thiel E,Hofmann WK

    更新日期：2009-03-01 00:00:00

  • New therapeutics for myelodysplastic syndromes.

    abstract：:While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinic...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2012.08.010

    authors： List AF

    更新日期：2012-12-01 00:00:00

  • Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

    abstract：:Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGF beta R and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic myelogenous leukemias and non-Hodgkin's lymphoma. Murine hematopoietic growth factor dependent BaF3 cells and cells transformed by FTK (BaF3-FTK) w...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00163-7

    authors： Hoser G,Majsterek I,Romana DL,Slupianek A,Blasiak J,Skorski T

    更新日期：2003-03-01 00:00:00

  • The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus.

    abstract：:The technology of array comparative genomic hybridization (array-CGH/aCGH) enabled the identification of novel genomic aberrations in chronic lymphocytic leukemia (CLL) including the monoallelic and biallelic deletions affecting 22q11 locus. In contrast to previous publications, we hypothesized that the described 22q1...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.03.018

    authors： Mraz M,Stano Kozubik K,Plevova K,Musilova K,Tichy B,Borsky M,Kuglik P,Doubek M,Brychtova Y,Mayer J,Pospisilova S

    更新日期：2013-07-01 00:00:00

  • Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia.

    abstract：:The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell diseases in which both diagnosis and prognosis are determined by cellular morphologic criteria. In some patients, prognosis is poor due to proliferation of immature cells, i.e. development of acute leukemia. An important clinical decisi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)90112-0

    authors： Woodlock TJ,Seshi B,Sham RL,Cyran EM,Bennett JM

    更新日期：1994-03-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.

    abstract：BACKGROUND:Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. F...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.01.002

    authors： Xiao D,Shi Y,Fu C,Jia J,Pan Y,Jiang Y,Chen L,Liu S,Zhou W,Zhou J,Tao Y

    更新日期：2016-03-01 00:00:00

  • Pluripoietin effects on CFU-S lineage determination: possible mechanisms.

    abstract：:Regulation of pluripotent stem cell (CFU-S) proliferation kinetics by humoral factors is now well documented. However, the mechanism of choice of CFU-S differentiation pathways is still a controversial issue. We suggest that long-range humoral factors (pluripoietins) are capable of preferentially channelling CFU-S tow...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90041-9

    authors： Frindel E,Vendrely C

    更新日期：1984-01-01 00:00:00

  • Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.

    abstract：:In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)00118-t

    authors： van der Hem KG,Dräger AM,Odding JH,Langenhuijsen MM,Huijgens PC

    更新日期：1995-01-01 00:00:00

  • Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

    abstract：:This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.08.009

    authors： Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

    更新日期：2009-04-01 00:00:00